Maintenance effect of a once-weekly regimen of a Selenium Disulfide-based shampoo in moderate-to-severe scalp seborrheic dermatitis after initial treatment with topical corticosteroid/salicylic acid.


Journal

European journal of dermatology : EJD
ISSN: 1952-4013
Titre abrégé: Eur J Dermatol
Pays: France
ID NLM: 9206420

Informations de publication

Date de publication:
01 Mar 2023
Historique:
medline: 28 4 2023
pubmed: 26 4 2023
entrez: 26 4 2023
Statut: ppublish

Résumé

Seborrheic dermatitis (SD) is a chronic, relapsing, inflammatory disorder of the head and trunk. To explore the potential of a 1% Selenium disulphide (SeS2)-based shampoo to prevent relapses of scalp SD (SSD) following corticosteroid/salicylic acid (TCS/SA) treatment. After a 2-week treatment with TCS/SA, adult patients with moderate-to-severe SSD received either the SeS2-based shampoo or its vehicle for eight weeks in a randomized, double-blinded fashion. Visits took place at baseline, weeks 2, 6 and 10. SSD severity was assessed based on erythema, flakes and pruritus; patients assessed the severity of pruritus. Global investigator and patient satisfaction were assessed at week 10. Forty-eight adults were included. After four and eight weeks of post TCS/SA maintenance regimen, 8.1% and 16.7% in the SeS2, and 41.7% and 54.2% in the vehicle group relapsed, respectively. First median time-to-relapse in the vehicle group was 56 days; this was not reached for SeS2. After two weeks of TCS/SA, the prevalence of patients with no pruritus was 29.2% in the SeS2 group, and 41.7% in the vehicle group; it increased to 76.2% with SeS2 and to 57.1% with the vehicle at the end of the study. The clinical benefit of treatment with TCS/SCA was maintained in the SeS2 group only. Investigators and patients were highly satisfied with the efficacy of SeS2. Tolerance to SeS2 was excellent, with no reported adverse events. The SeS2-based shampoo significantly reduces the time-to-relapse of moderate-to-severe SSD flares. Its tolerance was excellent, with no reported adverse events.

Identifiants

pubmed: 37098774
pii: ejd.2023.4401
doi: 10.1684/ejd.2023.4401
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Salicylic Acid O414PZ4LPZ
selenium disulfide Z69D9E381Q

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-18

Auteurs

Philippe Massiot (P)

L'Oréal Research and Innovation, Saint-Ouen, France.

Pascal Reygagne (P)

Centre Sabouraud, Hôpital Saint-Louis, 1, avenue Claude-Vellefaux, 75010 Paris, France.

Corinne Chagnoleau (C)

L'Oréal Research and Innovation, Saint-Ouen, France.

Leila Kanoun-Copy (L)

L'Oréal Research and Innovation, Saint-Ouen, France.

Florence Pouradier (F)

L'Oréal Research and Innovation, Saint-Ouen, France.

Geneviève Loussouarn (G)

L'Oréal Research and Innovation, Saint-Ouen, France.

Catherine Queille-Roussel (C)

CPCAD, Hôpital l'Archet Nice, France.

Hussein Jouni (H)

L'Oréal Research and Innovation, Aulnay-sous-Bois, France.

Delphine Kerob (D)

Cosmetic Active International, Levallois-Perret, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH